Orchestra BioMed Holdings (OBIO) Cost of Revenue (2022 - 2025)
Historic Cost of Revenue for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $49000.0.
- Orchestra BioMed Holdings' Cost of Revenue fell 2794.12% to $49000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $197000.0, marking a year-over-year increase of 207.25%. This contributed to the annual value of $204000.0 for FY2024, which is 967.74% up from last year.
- According to the latest figures from Q3 2025, Orchestra BioMed Holdings' Cost of Revenue is $49000.0, which was down 2794.12% from $46000.0 recorded in Q2 2025.
- In the past 5 years, Orchestra BioMed Holdings' Cost of Revenue registered a high of $68000.0 during Q3 2024, and its lowest value of $34000.0 during Q1 2024.
- Its 4-year average for Cost of Revenue is $49333.3, with a median of $47000.0 in 2023.
- As far as peak fluctuations go, Orchestra BioMed Holdings' Cost of Revenue soared by 6585.37% in 2024, and later plummeted by 2794.12% in 2025.
- Orchestra BioMed Holdings' Cost of Revenue (Quarter) stood at $53000.0 in 2022, then decreased by 11.32% to $47000.0 in 2023, then rose by 23.4% to $58000.0 in 2024, then decreased by 15.52% to $49000.0 in 2025.
- Its Cost of Revenue was $49000.0 in Q3 2025, compared to $46000.0 in Q2 2025 and $44000.0 in Q1 2025.